Exosomes carry the stem cell's signal to other cells.
Mesenchymal stem cells appear to work mainly by signaling. Exosomes are membrane-bound vesicles, roughly 30 to 150 nanometres across, released by MSCs and carrying the cell's payload of proteins and regulatory RNA to other cells.
Exosome preparations contain no live cells. A physician prescribes them as an adjunct to whole-cell therapy or on their own, delivered by injection, microneedling, or IV depending on the site.
We use exosomes in six groups of protocols.
Every protocol below appears in the TrueCell formulary today. Whether an exosome preparation belongs in your plan — and in what role — is always the physician's call, after your history and imaging are reviewed.
Joints
In the knee, exosomes are combined with whole-cell therapy. The exosome + UC‑MSC protocol adds the cell-free signal to the living-cell dose.
Exosome + UC‑MSC · intra-articularSpine
In the spine, exosomes are delivered intradiscally as one option in the formulary, alongside single- and multi-level UC‑MSC and Muse protocols.
Exosome · intradiscalFacial & skin
Exosomes are microneedled into the skin for facial rejuvenation and for scarring — acne scars, stretch marks, burn and surgical scars. A topical exosome serum is also available.
Microneedle · topical serumHair restoration
Exosomes are microneedled into the scalp for crown, hairline, beard, and eyebrows. An exosome maintenance series follows the initial course.
Scalp microneedle · maintenance seriesIV systemic
A systemic exosome infusion sits in the whole-body formulary next to UC‑MSC and Muse infusions, including the longevity and vitality protocols.
Exosome · systemic IVCondition protocols
Systemic exosome infusions also appear as options within the autoimmune and neurological protocol groups, where the physician may pair them with UC‑MSC therapy.
Exosome · systemic · physician-selectedThe vial contains a vesicle preparation.
An exosome preparation is a vesicle product. That single fact drives most of what makes the modality different from cell therapy.
30–150nm
is the size of an exosome — hundreds of times smaller than the cell that made it, and small enough to reach tissues that whole cells cannot.
0 live cells
Exosome preparations contain no live cells. A vesicle cannot divide, which in theory removes the concerns that come with delivering a living, replicating cell.
ISO‑certified
GMP laboratory. Each preparation is released only after sterility and identity verification — the same source standard as our cell products.
How the signal travels.
Tap a step to follow a vesicle from the parent cell to its target.
How exosomes compare to MSCs and PRP.
Exosomes sit alongside whole-cell MSC therapy and PRP in the formulary. Each is used in a different role, and the physician tailors the choice to your case.
Cell-free
Exosomes
Exosomes deliver the MSC's signaling payload and contain no living cells. They are easier to store, dose, and standardize, and small enough to reach tissues whole cells cannot.
We use exosomes as an adjunct layered onto cell therapy, or on their own in skin, hair, intradiscal, and systemic protocols. Human evidence is younger than for MSCs.
Living cells
Whole-cell MSC
A whole-cell dose delivers tens of millions of living cells that sense their environment and tune what they secrete in response.
We use whole-cell MSC therapy as the backbone of most joint, spine, and systemic protocols. It is the most established option in the formulary, with the deepest clinical evidence base.
From your own blood
PRP
Platelet-rich plasma is concentrated from your own blood — a familiar autologous preparation rather than a laboratory-expanded product.
We use PRP in combination protocols — PRP + UC‑MSC for joints, scalp, and skin — where it supports the primary regenerative agent.
The evidence, briefly.
Three anchor findings from the peer-reviewed exosome literature.
2007
was the year exosomes were shown to transfer mRNA and microRNA between cells — the landmark demonstration that they are a genuine genetic communication system.
Valadi H, et al. Nat Cell Biol, 2007.
Preclinical
MSC-secreted exosomes reduced tissue damage in a model of heart injury, reproducing a key effect of whole-cell therapy with a cell-free preparation.
Lai RC, et al. Stem Cell Res, 2010.
Review
A major review makes the case for MSC-derived exosomes as cell-free therapy, citing a simpler risk profile and product-like handling. Human validation is still under way.
Phinney DG & Pittenger MF. Stem Cells, 2017.
An honest note on where this stands: the clinical evidence for exosomes is younger than the evidence for whole-cell MSC therapy. The strongest results so far come from laboratory and animal studies; rigorous, controlled human trials remain limited, and the field is still working toward standard ways to isolate, characterize, and dose exosome products. No exosome product is FDA-approved for the conditions it is commonly marketed for. That is why we describe exosomes as a promising, mechanistically coherent modality rather than a settled one — and why whether one belongs in your protocol, and in what role, is decided by a board-certified physician after review of your history and imaging. Provided in México under COFEPRIS.
